Skip to content
  • Login / Register
  • Cart / $0.00
    • No products in the cart.

  • Add anything here or just remove it...
ichorbioichorbio
  • Products
    • Immune Checkpoint Molecules
      • CD40 Reagents
      • CD70 Reagents
      • CD86 Reagents
      • CTLA-4 Reagents
      • LAG-3 Reagents
      • PD-1 Reagents
      • PD-L1 Reagents
    • Nucleic Acid Stains
    • Research Biosimilars – All Products
    • Isotype Controls
    • Type I & Type II Interferons
    • Ultra-Pure Detergents
    • Mouse Immune Cell Depletion Antibodies
  • About Us
  • Resources
    • Comparing ichorbio to Bio X Cell and BioLegend: Product Attributes
    • Amazon Vouchers for Reviews
    • How to Write a Great Life Science Paper
  • Distribution Network
  • Contact Us
  • Cart

    No products in the cart.

Home / Antibodies / Low Endotoxin
  • 2020 FDA Approvals Bevacizumab
  • 2020 FDA Approvals Atezolizumab
Filter
2020 FDA Approvals Avelumab

Avelumab Biosimilar – Research Grade [ICH4017]

$704.00 – $4,080.00

Clear
2020 FDA Approvals Avelumab
Avelumab Biosimilar – Research Grade [ICH4017]

— OR —

SKU: ICH4017 Categories: anti-human, Biosimilar Antibodies, Low Endotoxin
Browse
  • Antibodies
    • Biosimilar Antibodies
    • Isotype Controls
    • Low Endotoxin
    • Ultra Low Endotoxin
  • Antibody Labeling Kits
  • Applications
    • Blocking
    • CODEX
    • CyTOF
    • Dot Blot
    • ELISA
    • ELISpot
    • Flow Cytometry
    • Flow Cytometry (intracellular)
    • Functional Assays
    • IHC (Frozen)
    • IHC (Paraffin)
    • ImmunoCytoChemistry
    • Immunofluorescence
    • Immunoprecipitation
    • In Situ Hybridization
    • In Vivo Depletion
    • IP-Mass Spectrometry
    • Neutralization
    • Western Blot
  • Conjugated
    • APC
    • Biotin
    • DyLight 488
    • DyLight 550
    • DyLight 594
    • DyLight 633
    • DyLight 650
    • DyLight 680
    • DyLight 755
    • DyLight 800
    • FITC
    • PE
    • PE/Cy7
    • PerCP
  • Detergents
  • Fc-Silenced
  • Gel Stain
  • Inhibitors
  • Recombinant Proteins
  • Species Reactivity
    • anti-bovine
    • anti-chicken
    • anti-human
    • anti-mouse
    • anti-rat
    • Monkey
  • Description
  • Additional information
  • Reviews (0)

Bulk Avelumab Biosimilar – Research Grade

Product Benefits:
ichorbio’s Avelumab Biosimilar – Research Grade is manufactured in a cGMP compliant facility. ichorbio offers Amazon vouchers or donations to the NC3Rs for reviews of this product: click here for more information. ichorbio: the best antibodies for in vivo research.
Size:
ichorbio’s research grade avelumab biosimilar is available in the following sizes:
5mg, 10mg, 20mg, 50mg
ichorbio regularly manufactures bulk multi-gram amounts of our avelumab biosimilar – please contact us for pricing.
Target:
PD-L1
Clone:
n/a
Isotype:
IgG1 lambda
Other Names:
Programmed cell death 1 ligand 1, Cd274, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, PDL-1
Host:
Humanized
Species Reactivity:
Human
Specificity:
Detects human PD-L1. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Avelumab.
Purification Method:
This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background:
Avelumab biosimilar is a programmed death ligand-1 (PD-L1) blocking antibody. Avelumab is a human IgG1 lambda monoclonal antibody that has a molecular weight of approximately 147 kDa.
Concentration:
1.0 – 5.0 mg/ml
Formulation:
0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added. BSA and Azide free.
Purity:
>95% by SDS-PAGE and HPLC
Endotoxin:
≤ 0.75 EU/mg as determined by the LAL method
Storage:
Avelumab Biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Applications:
Functional Assays
Application Notes:
Each investigator should determine their own optimal working dilution for specific applications.
Use:

ichorbio’s avelumab biosimilar is for research use only: it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Recent Research into Avelumab:

Avelumab is a human IgG1 monoclonal antibody directed against the immunosuppressive ligand PD-L1 (programmed death-ligand 1) that prevents its interaction with the inhibitory T-cell receptor, PD-1 (programmed cell death protein 1). Upon binding, avelumab promotes T-cell reactivation and restores T-cell-mediated immune response against tumor cells. Avelumab is also the only PD-L1 antibody so far to also induce antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing PD-L1. It was first approved by the FDA in March 2017 for the treatment of patients with metastatic MCC (Merkel cell carcinoma) and later for advanced types of renal cell carcinoma and urothelial cancer. Here are some examples of avelumab’s latest research on advanced and metastatic cancer treatments.

In one of the latest studies published in Cell, Chew et al. (2020) hypothesized that inhibition of endocytosis may improve the efficiency of immunotherapeutic antibodies on the clinical outcome of advanced cancer patients. Using PCZ, a dynamin inhibitor in combination with avelumab, they significantly improved the therapeutic response in mice with CT26.WT tumors in terms of tumor growth and clearance. Their data in vivo showed that this was due to an increase in avelumab-mediated ADCC and the induction of a potent immune response against tumor cells. In this study, the temporary inhibition of endocytosis increased tumor cell antigen presentation and target availability for immunotherapeutic agents such as cetuximab, trastuzumab, and avelumab.

In early 2020, Tafuri et al. performed a meta-analysis on the response rates of patients treated with PD-1 and PD-L1 inhibitors with urothelial carcinoma refractory to standard treatment. The study focused on five FDA-approved antibodies targeting PD-1 or PD-L1: atezolizumab, durvalumab, avelumab, nivolumab, and pembrolizumab. The authors analyzed objective and complete responses, as well as median overall survival and progression-free survival. They measured higher estimated response rates for the selected antibodies than for the “other salvage therapies”.

In January 2020, Elbers et al. published the results of a phase-I feasibility trial for advanced-stage head and neck squamous cell carcinoma (HNSCC) patients unfit for cisplatin treatment. The alternative treatment for these patients consists of radiotherapy with cetuximab but the low 5-year overall survival still highlights the need to improve the current therapy strategy. In this study, the authors tested a combination of cetuximab and PD-L1 immune checkpoint blockade with avelumab. They observed transient and manageable immune-related toxicity that did not impact the toxicity of radiotherapy alone. Based on their results, they concluded that the combination treatment was feasible and needed to be tested on a larger scale.

At around the same time, another group conducted a meta-analysis with 6,896 participants in 26 different studies to investigate the incidence and potential factors of fatal adverse events associated with the use of PD-L1 inhibitors for the treatment of patients with advanced cancer. The search was performed on PubMed, Embase, and the Cochrane Library and included four PD-L1 inhibitors: atezolizumab, durvalumab, avelumab, and cemiplimab. The overall incidence of fatal adverse events associated with PD-L1 inhibitors was 1.24%. Interestingly, the incidence of fatal adverse events associated with avelumab was lower than that of both atezolizumab and durvalumab.

Keywords: PDL1; PD1; immune checkpoints; avelumab; advanced tumors.

References:

Akintunde Akinleye & Zoaib Rasool. (2019). Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. Journal of Hematology & Oncology volume 12, Article number: 92 (2019)

Chew HY, De Lima PO, Gonzalez Cruz JL, Banushi B, et al. (2020). Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell. 2020 Mar 5;180(5):895-914

Elbers JBW, Al-Mamgani A, Tesseslaar MET, van den Brekel MWM, Lange CAH, van der Wal JE, Verheij M, Zuur CL, de Boer JP. (2020). Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial. Radiother Oncol. 2020 Jan;142:79-84.

Tafuri A, Smith DD, Cacciamani GE, Cole S, Shakir A, Sadeghi S, Vogelzang NJ, Quinn D, Gill PS, Gill IS. (2020). Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. Clin Genitourin Cancer. 2020 Jan 31.

Wang X, Wu S, Chen Y, Shao E, Zhuang T, Lu L, Chen X. (2020). Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020 Jan 31;11:5.

Size:

2mg, 5mg, 10mg, 20mg, 25mg, 50mg, 100mg

Reviews

There are no reviews yet.

Be the first to review “Avelumab Biosimilar – Research Grade [ICH4017]” Cancel reply

Related products

+
Quick View

Isotype Controls

Mouse IgG3 Isotype Control for In Vivo – Low Endotoxin (MG3-35) [ICH2249]

$320.00 – $2,378.00
+
Quick View

anti-mouse

Anti-CD86 In Vivo Antibody – Low Endotoxin (GL1) [ICH1038]

$320.00 – $2,378.00
+
Quick View

Isotype Controls

Mouse IgG2b Isotype Control for In Vivo – Low Endotoxin (MPC-11) [ICH2250]

$320.00 – $2,378.00
+
Quick View

anti-mouse

Anti-CD62L In Vivo Antibody – Low Endotoxin (MEL-14) [ICH1060]

$320.00 – $2,140.00
About us

From Oxford, United Kingdom - ichorbio supplies the best antibodies for in vivo research. Our in vivo antibodies are sold for the purposes of research only, not for therapeutic or diagnostic use.

ichorbio Ltd, Grove Business Park, Downsview Road, Wantage OX12 9FF

Our best selling in vivo antibodies:

  • CTLA-4 in vivo antibody (9H10)
  • CTLA-4 in vivo antibody (9D9)
  • HLA-DP in vivo antibody (B7/21)
  • IFNAR1 in vivo antibody (MAR1-5A3)
  • PD-1 in vivo antibody (RMP1-14)
  • PD-L1 in vivo antibody (10F.9G2)
  • TNF-alpha in vivo antibody (TN3-19.12)

Our best selling Research Grade Biosimilars:

  • Atezolizumab - Research Grade
  • Avelumab - Research Grade
  • Eculizumab - Research Grade
  • Ipilimumab - Research Grade
  • Nivolumab - Research Grade
  • Ofatumumab - Research Grade
  • Pembrolizumab - Research Grade
  • A Beginner’s Guide to Writing a Life Science Paper
  • Comparing ichorbio to Bio X Cell and BioLegend: Product Attributes
  • Terms & Conditions
  • Privacy Policy
Copyright 2021 © ichorbio .
  • Products
    • Immune Checkpoint Molecules
      • CD40 Reagents
      • CD70 Reagents
      • CD86 Reagents
      • CTLA-4 Reagents
      • LAG-3 Reagents
      • PD-1 Reagents
      • PD-L1 Reagents
    • Nucleic Acid Stains
    • Research Biosimilars – All Products
    • Isotype Controls
    • Type I & Type II Interferons
    • Ultra-Pure Detergents
    • Mouse Immune Cell Depletion Antibodies
  • About Us
  • Resources
    • Comparing ichorbio to Bio X Cell and BioLegend: Product Attributes
    • Amazon Vouchers for Reviews
    • How to Write a Great Life Science Paper
  • Distribution Network
  • Contact Us
  • Login

Login

Lost your password?

Register

A password will be sent to your email address.

Your personal data will be used to support your experience throughout this website, to manage access to your account, and for other purposes described in our privacy policy.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok